Chemical Information
Antiviral agent ID	DrugRepV_3420
Antiviral agent name	Dapivirine
IUPAC Name	4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
SMILES (canonical)	CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C
Molecular Formula	C20H19N5
Molecular Weight (g/mol)	329.407
InChl	InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)
Common Name	Dapivirine
Synonyms	4-((4-(mesitylamino)pyrimidin-2-yl)amino)benzonitrile | Dapivirinum | DapivirineTMC-120 | Ring-004 | 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
Structural Information
Clinical Information
Primary Indication (Clinical trial phases)	Investigational
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Acquired immunodeficiency syndrome
Secondary Indication	Influenza virus (IAV) H1N1 A/WSN/1933 (H1N1)
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	A549
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.01 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	24 hours
Secondary Indication (Drug concentration)	3 μM
Secondary Indication (Cell based assay)	Plaque assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	Log reduction [ 1.7 Log ]
Reference	Hu Y, Zhang J, Musharrafieh RG, Ma C, Hau R, Wang J..Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum.Antiviral Res. 2017 Sep;145:103-113. doi: 10.1016/j.antiviral.2017.07.016. Epub 2017 Aug 2. PMID:28778830
Comment	Dapivirine inhibits the nuclear entry of viral ribonucleoproteins at the early stage of viral replication. As a result, viral RNA and protein synthesis were inhibited